T cell replacement therapy (Armata Pharmaceuticals)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameT cell replacement therapy (Armata Pharmaceuticals)
Drug Alias NameT lymphocyte therapyT cell therapyT cell activation therapy
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsMelanomaCytomegalovirus InfectionsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesFred Hutchinson Cancer Research Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFred Hutchinson Cancer Research CenterArmata Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsMelanomaCytomegalovirus InfectionsHIV Infections

Other Information

ATC CodeN/A
Related LinksN/A